Watch for Injectable Semaglutide to Treat Fatty Liver

June 2026

The latest indication for injectable semaglutide (Wegovy) will increase focus on metabolic dysfunction-associated steatohepatitis (MASH).

About 15 million adults in the US have MASH...and it’s on the rise.

MASH is when fat builds up in the liver...leading to inflammation and liver damage. If left untreated, it can progress to fibrosis (or scarring), cirrhosis, liver failure, or death.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Emergency Medicine Help Your Team Manage Medetomidine Overdoses and Withdrawal
Venous Thromboembolism Meds for Pulmonary Embolism: What Pharmacy Techs Should Know
Practice Help Patients Navigate AI Medical Info Safely
UTIs Support Safe Transitions of Care Around Recurrent UTIs
Rumor vs Truth Listen for Questions About Off-Label Uses for Ivermectin
Fall Risk Be Familiar With Meds That Increase Fall Risk
Liver Disease Watch for Injectable Semaglutide to Treat Fatty Liver
Calculations Make Alligation Calculations as Easy as Tic-Tac-Toe

Watch for Injectable Semaglutide to Treat Fatty Liver

Practical advice for a better career, with unlimited access to CE

Table of Contents